Skip to main content
LB

Landmark Bio

Landmark Bio is a cell and gene therapy contract development and manufacturing organization (CDMO) that specializes in process and analytical development, formulation, and quality control testing to facilitate the transition of therapies from research to clinical application. The company addresses the challenges of manufacturing scalability and regulatory compliance for biopharma leaders, enabling them to meet critical milestones efficiently.

Boston, United StatesFounded 2021683K+ followers
Updated 4 months ago

Funding

$280K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

The transition of cell and gene therapies from research to clinical application faces significant hurdles in manufacturing scalability, regulatory compliance, and analytical development. Biopharma companies often struggle to efficiently navigate these challenges, hindering their ability to meet critical milestones and deliver therapies to patients.

Solution

Landmark Bio is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, providing comprehensive services to accelerate the transition from research to clinical application. The company offers process and analytical development, formulation, quality control testing, and CMC consulting to address manufacturing scalability and regulatory compliance challenges. Landmark Bio acts as a partner for academic researchers, physician scientists, and biopharma leaders, offering services to remove obstacles, maximize efficiency, and meet milestones at an accelerated pace. By focusing on innovative technologies, products, and services, Landmark Bio bridges the gap between bench and patient, helping clients achieve their clinical and commercial aspirations.

Target Audience

Landmark Bio serves academic researchers vetting therapeutic targets, physician scientists preparing for IND filings, and biopharma leaders advancing their pipeline products to the clinic.

Features

  • Process and analytical development for cell and gene therapies
  • Formulation development to optimize therapeutic delivery
  • Cell and gene therapy manufacturing services
  • Fill & Finish services
  • Quality control testing to ensure product safety and efficacy
  • CMC consulting to navigate regulatory requirements
  • IND enabling services to support clinical trial applications
  • Technology development to advance therapeutic manufacturing
This profile is AI-generated and may contain inaccuracies.